Noël G, Boisserie G, Dessard-Diana B, Ferrand R, Hasboun D, Gasowski M, Desblancs C L, Simon J M, Baillet F, Mazeron J J
Centre de protonthérapie, BP 65, 91402 cedex, Orsay, France.
Cancer Radiother. 2002 Dec;6(6):337-48. doi: 10.1016/s1278-3218(02)00222-6.
Purpose- There is a relationship between the local control rate of the nasopharyngeal cancer and the total dose delivered within the tumoral volume. In contrast, the relation between the dose and the irradiated volume and the risk of complication is not clearly defined. That is why, in patients presenting with a locally advanced nasopharyngeal cancer, we compared the dose-volume distribution of irradiated tissues, obtained from two 3D conformal irradiation techniques. Patients and methods- Between January 2000 and June 2001, 5 patients, 3 males and 2 females, with a median age of 32 years and presenting with a T4N0M0 nasopharyngeal cancer received a chemoradiotherapy. Radiotherapy combined photons and protons beams and the platin-based chemotherapy was delivered in three intravenous injections at d1, 22, 43 of the irradiation. To calculate the dosimetry, a CT scan and a MRI were performed in all the patients. The gross tumor volume (GTV) was delineated from the imagery, three clinical tumor volumes were defined, the CTV1 was the GTV and the whole nasopharynx, the CTV2 was the CTV plus a 10 mm-margin and the CTV3 was the CTV2 and the nodes areas (cervical and subclavicular). Prophylactic dose within node areas was 44 Gy. Prescribed doses within CTV2 and GTV or CTV1 were 54 Gy/CGE (Cobalt Gy Equivalent, for an EBR = 1,1) and 70 Gy/CGE, respectively. Irradiation was delivered with fractions of 1.8 or 2.0 Gy/CGE, with 44 Gy or 54 Gy by photons and with 16 or 26 CGE by protons. According to dose-volume histograms obtained from the dosimetry planning by protons and photons and from the theoretical dosimetry by photons lonely, for the different volumes of interest, GTV, CTV2, and organs at risk (optic nerves, chiasm, internal ears, brainstem, temporal lobes), we compared the averages of the maximum, minimum and mean doses and the averages of the volumes of organs of interest encompassed by different isodoses.Results- Calculated averages of minimum, maximum and mean doses delivered within GTV were superior for the treatment with combined photons and protons than with photons alone. The average GTV encompassed by the 70 Gy/CGE isodose was larger by 65% with the association compared to photons alone. The conformation ratio (tissue volume encompassed by the 95% isodose/GTV encompassed by the 95% isodose) was 3.1 with the association compared to 5.7 with photons alone. For the CTV2, there were no differences in different criteria according to the both irradiation techniques. For the critical, radiosensitive organs, the comparison of the majority of the criteria was in favour of the association of protons and photons. Overall, 78% of the criteria were in favour of the association.Conclusion- For locally advanced nasopharyngeal cancer without clinical adenopathy, irradiation by photons and protons increases the tumor volume irradiated at the prescribed dose and decreases the volume or critical organs irradiated and the total dose delivered within them.
目的——鼻咽癌的局部控制率与肿瘤体积内所给予的总剂量之间存在关联。相比之下,剂量与照射体积以及并发症风险之间的关系尚不明确。因此,对于局部晚期鼻咽癌患者,我们比较了两种三维适形照射技术所获得的照射组织的剂量体积分布。
患者与方法——2000年1月至2001年6月期间,5例患者(3例男性,2例女性),中位年龄32岁,患有T4N0M0鼻咽癌,接受了放化疗。放疗联合光子束和质子束,铂类化疗在照射的第1天、第22天和第43天进行三次静脉注射。为了计算剂量学,所有患者均进行了CT扫描和MRI检查。从影像中勾勒出大体肿瘤体积(GTV),定义了三个临床肿瘤体积,CTV1为GTV和整个鼻咽部,CTV2为CTV加上10mm的边缘,CTV3为CTV2和淋巴结区域(颈部和锁骨下)。淋巴结区域的预防剂量为44Gy。CTV2和GTV或CTV1内的处方剂量分别为54Gy/CGE(钴当量Gy,对于电子束放疗=1.1)和70Gy/CGE。照射采用1.8或2.0Gy/CGE的分次剂量,光子照射剂量为44Gy或54Gy,质子照射剂量为16或26CGE。根据质子和光子剂量学计划以及仅光子理论剂量学所获得的剂量体积直方图,对于不同的感兴趣体积,即GTV、CTV2和危及器官(视神经、视交叉、内耳、脑干、颞叶),我们比较了最大、最小和平均剂量的平均值以及不同等剂量线所包含的感兴趣器官体积的平均值。
结果——联合光子和质子治疗时,GTV内所给予的最小、最大和平均剂量的计算平均值高于单纯光子治疗。与单纯光子治疗相比,联合治疗时70Gy/CGE等剂量线所包含的平均GTV大65%。联合治疗时的适形比(95%等剂量线所包含的组织体积/95%等剂量线所包含的GTV)为3.1,而单纯光子治疗时为5.7。对于CTV2,根据两种照射技术,不同标准下均无差异。对于关键的、放射敏感器官,大多数标准的比较结果支持质子和光子联合治疗。总体而言,78%的标准支持联合治疗。
结论——对于无临床淋巴结肿大的局部晚期鼻咽癌,光子和质子照射增加了在处方剂量下照射的肿瘤体积,减少了照射的关键器官体积以及其中所给予的总剂量。